1. Market Research
  2. > Business Services
  3. > Research and Development Market Trends
  4. > Xiber Science GmbH - Product Pipeline Review - 2014

Xiber Science GmbH - Product Pipeline Review - 2014

  • November 2014
  • -
  • Global Markets Direct
  • -
  • 20 pages

Xiber Science GmbH - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘Xiber Science GmbH - Product Pipeline Review - 2014’, provides an overview of the Xiber Science GmbH’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Xiber Science GmbH’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Xiber Science GmbH including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Xiber Science GmbH’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Xiber Science GmbH’s pipeline products

Reasons to buy

- Evaluate Xiber Science GmbH’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Xiber Science GmbH in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Xiber Science GmbH’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Xiber Science GmbH and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Xiber Science GmbH
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Xiber Science GmbH and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Xiber Science GmbH - Product Pipeline Review - 2014
Table of Contents

Xiber Science GmbH Snapshot 4
Xiber Science GmbH Overview 4
Key Information 4
Key Facts 4
Xiber Science GmbH - Research and Development Overview 5
Key Therapeutic Areas 5
Xiber Science GmbH - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Xiber Science GmbH - Pipeline Products Glance 9
Xiber Science GmbH - Early Stage Pipeline Products 9
Preclinical Products/Combination Treatment Modalities 9
Discovery Products/Combination Treatment Modalities 10
Xiber Science GmbH - Drug Profiles 11
Xib-1301 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
Xib-05 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
Xib-1302 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
Xib-1303 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
Xib-1304 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
Xiber Science GmbH - Pipeline Analysis 16
Xiber Science GmbH - Pipeline Products by Route of Administration 16
Xiber Science GmbH - Pipeline Products by Molecule Type 17
Xiber Science GmbH - Locations And Subsidiaries 18
Head Office 18
Appendix 19
Methodology 19
Coverage 19
Secondary Research 19
Primary Research 19
Expert Panel Validation 19
Contact Us 20
Disclaimer 20

List of Tables

Xiber Science GmbH, Key Information 4
Xiber Science GmbH, Key Facts 4
Xiber Science GmbH - Pipeline by Indication, 2014 6
Xiber Science GmbH - Pipeline by Stage of Development, 2014 7
Xiber Science GmbH - Monotherapy Products in Pipeline, 2014 8
Xiber Science GmbH - Preclinical, 2014 9
Xiber Science GmbH - Discovery, 2014 10
Xiber Science GmbH - Pipeline by Route of Administration, 2014 16
Xiber Science GmbH - Pipeline by Molecule Type, 2014 17

List of Figures

Xiber Science GmbH - Pipeline by Top 10 Indication, 2014 6
Xiber Science GmbH - Pipeline by Stage of Development, 2014 7
Xiber Science GmbH - Monotherapy Products in Pipeline, 2014 8
Xiber Science GmbH - Pipeline by Top 10 Route of Administration, 2014 16
Xiber Science GmbH - Pipeline by Top 10 Molecule Type, 2014 17

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016’, provides in depth analysis on Integrin Alpha 7 (ITGA7) ...

Pulmonary Fibrosis - Pipeline Review, H2 2016

Pulmonary Fibrosis - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Pulmonary Fibrosis - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Pulmonary Fibrosis - Pipeline Review, H2 2016’, provides an overview of the Pulmonary Fibrosis pipeline landscape. ...

Cognitive Impairment - Pipeline Review, H2 2016

Cognitive Impairment - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Cognitive Impairment - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Cognitive Impairment - Pipeline Review, H2 2016’, provides an overview of the Cognitive Impairment pipeline landscape. ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.